Literature DB >> 8892027

Severe hyperprostaglandin E syndrome with hyperthyroidism--studies of pathogenetic mechanisms.

V Fellman1, H Pihko, A Majander, H W Seyberth.   

Abstract

Hyperprostaglandin E syndrome is a rare disease usually presenting with renal symptoms such as polyuria, polyhydramnios, hypercalciuria, hypokalaemia, and recurrent episodes of extreme fever, diarrhoea, and convulsions. We report a severe variant of this syndrome with obvious pain and prostaglandin E2 (PGE2)-stimulated hyperthyroidism, an association not previously described. Urinary excretion of PGE2 and its metabolite 7 alpha-hydroxy-5,11-diketotetranorprosta-1,16-dioic acid were markedly increased above normal levels (to 53.3 and 1895 ng/h per 1.73 m2, respectively). We studied oxidative capacity of peroxisomes and mitochondria, the sites where PGE2 oxidation takes place. A generalized mitochondrial disease could be ruled out and no deficiency was found in liver peroxisomal oxidases. The basic pathology of hyperprostaglandin E syndrome remains unsolved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892027     DOI: 10.1007/bf01799846

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

Review 1.  Cellular mechanisms of prostaglandin E2 and vasopressin interactions in the collecting duct.

Authors:  M D Breyer; H R Jacobson; R L Hebert
Journal:  Kidney Int       Date:  1990-10       Impact factor: 10.612

2.  A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study.

Authors:  R LUFT; D IKKOS; G PALMIERI; L ERNSTER; B AFZELIUS
Journal:  J Clin Invest       Date:  1962-09       Impact factor: 14.808

3.  Production of a non-immunoglobulin thyroid stimulator by human lymphocytes during mixed culture with human thyroid cells.

Authors:  B Rapoport; R J Pillarisetty; E A Herman; O H Clark; E G Congco
Journal:  J Biol Chem       Date:  1978-01-25       Impact factor: 5.157

Review 4.  The role of eicosanoids in paediatrics.

Authors:  H W Seyberth; P G Kühl
Journal:  Eur J Pediatr       Date:  1988-05       Impact factor: 3.183

5.  Determination of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid and 9 alpha,11 alpha-dihydroxy-15-oxo-2,3,4,5,20-pentanor-19-carboxyprostanoi c acid by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.

Authors:  H Schweer; C O Meese; H W Seyberth
Journal:  Anal Biochem       Date:  1990-08-15       Impact factor: 3.365

6.  The arachidonic acid signal system in the thyroid: regulation by thyrotropin and insulin/IGF-I.

Authors:  K Tahara; M Saji; S M Aloj; L D Kohn
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

7.  Substrate specificities of rat liver peroxisomal acyl-CoA oxidases: palmitoyl-CoA oxidase (inducible acyl-CoA oxidase), pristanoyl-CoA oxidase (non-inducible acyl-CoA oxidase), and trihydroxycoprostanoyl-CoA oxidase.

Authors:  P P Van Veldhoven; G Vanhove; S Assselberghs; H J Eyssen; G P Mannaerts
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

8.  The CoA esters of 2-methyl-branched chain fatty acids and of the bile acid intermediates di- and trihydroxycoprostanic acids are oxidized by one single peroxisomal branched chain acyl-CoA oxidase in human liver and kidney.

Authors:  G F Vanhove; P P Van Veldhoven; M Fransen; S Denis; H J Eyssen; R J Wanders; G P Mannaerts
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

9.  Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.

Authors:  A Leonhardt; G Timmermanns; B Roth; H W Seyberth
Journal:  J Pediatr       Date:  1992-04       Impact factor: 4.406

10.  Impaired degradation of prostaglandins and thromboxane in Zellweger syndrome.

Authors:  J Fauler; D Tsikas; E Mayatepek; D Keppler; J C Frölich
Journal:  Pediatr Res       Date:  1994-10       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.